Phase 1 clinical study of highly purified natural killer (NK) cell infusion for patients with refractory digestive/gastrointestinal cancer to standard therapy

Trial Profile

Phase 1 clinical study of highly purified natural killer (NK) cell infusion for patients with refractory digestive/gastrointestinal cancer to standard therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs Natural killer cell therapy-Takara-Bio (Primary)
  • Indications Gastrointestinal cancer
  • Focus Adverse reactions
  • Sponsors Takara Bio
  • Most Recent Events

    • 13 May 2014 New trial record
    • 09 Apr 2014 Status changed from active, no longer recruiting to completed, based on reported results.
    • 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR-2014).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top